Search

Home > New FDA Approvals > 133 – Baricitinib for moderately-to-severely active rheumatoid arthritis; LBS-007 for ALL; FDA statements on youth use of, and access to, JUUL and other e-cigarettes and Fiscal Year 2019 budget


	Podcast:		New FDA Approvals
	Episode:		133 – Baricitinib for moderately-to-severely active rheumatoid arthritis; LBS-007 for ALL; FDA statements on youth use of, and access to, JUUL and other e-cigarettes and Fiscal Year 2019 budget
	Category:		Science & Medicine
	Duration:		00:10:19
	Publish Date:		2018-04-25 06:00:00
	Description:		April 25, 2018 Please subscribe, rate and review if you like this podcast. Thank you! The podcast website is http://newfdaapprovals.com 0:49 FDA advisory committee recommends the approval of baricitinib 2mg, but not 4mg, for the treatment of moderately-to-severely active rheumatoid arthritis https://www.prnewswire.com/news-releases/fda-advisory-committee-recommends-the-approval-of-baricitinib-2mg-but-not-4mg-for-the-treatment-of-moderately-to-severely-active-rheumatoid-arthritis-300634959.html 3:22 Lin BioScience Announces FDA Orphan Drug Designation for LBS-007 for the Treatment of Acute Lymphoblastic Leukemia https://www.prnewswire.com/news-releases/lin-bioscience-announces-fda-orphan-drug-designation-for-lbs-007-for-the-treatment-of-acute-lymphoblastic-leukemia-300635205.html 4:49 Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for testimony before a U.S. Senate Committee on Appropriations on FDA’s Fiscal Year 2019 budget https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm605539.htm 7:20 Statement from FDA Commissioner Scott Gottlieb, M.D., on new enforcement actions and a Youth Tobacco Prevention Plan to stop youth use of, and access to, JUUL and other e-cigarettes https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm605432.htm Brought to you by Nascent Medical. For assistance with medical writing, please email info@nascentmc.com. Music credit: freemusicarchive.org/music/MindsEye/Yellow_Taxi/
	Total Play:		0